title: Yttrium-90 microsphere radioembolization for hepatocellular carcinoma.
abstract: Yttrium-90 (Y90) radioembolization is an emerging strategy to treat liver malignancies, and clinical data supporting its use have accumulated in recent years. Y90-radioembolization has shown clinical effectiveness in intermediate and advanced hepatocellular carcinoma, with a favorable safety profile. Retrospective data show similar levels of effectiveness to transarterial chemoembolization in intermediate hepatocellular carcinoma, with some evidence of better tolerance. While phase 3 studies comparing Y90-radioembolization to chemoembolization in intermediate hepatocellular carcinoma would be difficult to conduct, studies comparing or combining Y90-radioembolization with sorafenib are under way. Questions also remain about the most suitable modalities for defining the dose to administer. Phase 3 studies are under way to clarify the place of Y90-radioembolization in the algorithm of HCC treatment.
authors.affiliation: Medical Oncology, Eugene Marquis Comprehensive Cancer Center, Rennes, France.
authors.forename: Julien
authors.initials: J
authors.lastname: Edeline
authors.affiliation: Medical Oncology, Paoli Calmette Institute, Marseille, France.
authors.forename: Marine
authors.initials: M
authors.lastname: Gilabert
authors.affiliation: Nuclear Medicine, Eugene Marquis Comprehensive Cancer Center, Rennes, France.
authors.forename: Etienne
authors.initials: E
authors.lastname: Garin
authors.affiliation: Medical Oncology, Eugene Marquis Comprehensive Cancer Center, Rennes, France.
authors.forename: Eveline
authors.initials: E
authors.lastname: Boucher
authors.affiliation: Medical Oncology, Paoli Calmette Institute, Marseille, France.
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Raoul
keywords: Hepatocellular carcinoma; Radioembolization; Review; Transarterial therapies; Yttrium-90